Recently,BioGeometry, a cutting-edge digital biotech company, has reached a strategic cooperation with GinnoVax, an innovative vaccine research, development, and industrialization enterprise.Both parties decided,Jointly develop innovative blood/respiratory, vector-borne infectious disease vaccines and antibody products, and build a generative AI-powered vaccine design technology platform., accelerating the development of vaccines produced in China into the intelligent era.
Vaccines are an important means of preventing and controlling diseases, but traditional technology vaccine research and development cycles are long, costly, and risky. With the development of geometric deep learning and generative AI technologies, artificial intelligence is being increasingly applied in the research and development of broad-spectrum enhanced vaccines, particularly in protein design and optimization.The appropriate introduction of AI models can greatly accelerate the development process of new vaccines, increase the success rate of research, and even turn previously unachievable vaccine design concepts into reality., to achieve the mission of promoting intelligent and innovative vaccination and advancing public health.BioGeometry focuses on building a generative AI protein design platform to empower the biopharmaceutical and biomanufacturing fields.Its core team was the first to apply diffusion generative models to the three-dimensional structure generation of molecules in 2021, with a key paper ranking in the top 50 most cited in the AI field in 2022.In June this year, BioGeometry released GeoFlow, a large protein design model.By integrating sequence and structure big data, and combining geometric deep learning with flow-matching generative models, GeoFlow has become the first generative AI protein design model to reach the AlphaFold3 level in antigen-antibody complex prediction tasks, following Google Deepmind. Currently,GeoFlow has been fully integrated into BioGeometry's GeoBiologics protein computing platform, successfully implemented in multiple fields such as de novo antibody design, enzyme mining, and antigen engineering, helping customers quickly achieve design + validation, and find target molecules faster and more accurately., bringing customers a brand-new protein design and optimization experience.GinoVax focuses on the research and industrialization of innovative vaccines, with comprehensive capabilities in innovative vaccine development.The company has established antigen intelligent design technology, reverse genetic vaccine strain rapid recombination technology, recombinant nanoparticle technology, innovative RNA vaccine technology, vaccine adjuvant technology, polysaccharide conjugation technology, RNA vaccine technology, needle-free injection vaccine technology, and non-injection rapid immunization vaccine technology, etc.Six major innovative vaccine technology platforms, achieving full-chain coverage of key elements in innovative vaccine R&D — vaccine intelligent design, nanoparticle antigens, innovative adjuvants, polysaccharide conjugates, and new dosage forms.The GenoVax team has extensive experience in vaccine product research and development, production, and market-related fields. They have long-term expertise in vaccine antigen design, CHO cell expression, formulation, and clinical research, with experience in the development and production of innovative vaccines through multiple technological routes.Through this strategic cooperation, both parties will leverage their respective strengths to carry out in-depth collaboration in the research and development and industrialization of innovative vaccines. Together, they will create innovative vaccine products made in China, making more substantial contributions to advancing disease prevention and benefiting human health.Founder & CEO of BioGeometryDr. Tang JianConfirmed as a guest to attend SynBioM 2024, the 2nd Summit on Synthetic Biological Manufacturing and Technology Application Industry, bringing a speech related to synthetic biology. Teachers who are interested are welcome to participate in the on-site exchange!
【SynBioM 2024】The 2nd Synthetic Biology Manufacturing and Technology Application Industry SummitOrganized and planned by BioGeometry, it will be held onNovember 13-14, 2024InShanghaiOfficially convening, the event will invite distinguished guests including professors and experts engaged in synthetic biology research, leading entrepreneurs, industry practitioners, and others to jointly explore and exchange ideas on the innovative applications of synthetic biology technology and the future industrial development trends. Hot topics in the industry will be discussed around technical applications in pharmaceuticals, agriculture, food, personal care and cosmetics, bio-based materials, energy, and more, constructing a collaborative platform for industry-university-research exchanges!（Meeting Details:20+ Guests Confirmed! Scholars and Enterprises from Multiple Fields of Synthetic Biology to Meet in Shanghai!）
To promote cooperation and exchange in the field of synthetic biology, the SynBioM editor has decided to establish a community communication group for industry-related professionals to communicate. Due to the number of group members exceeding200Human beings can onlyInvitation MethodJoin the group,Please add the editor's WeChat below to join the group., Add remarks:Company + Position + Name，Due to the heavy workload, individuals without remarks will not be approved.
